Cumberland Pharmaceuticals (NASDAQ:CPIX) Announces Earnings Results, Misses Estimates By $0.07 EPS

Cumberland Pharmaceuticals (NASDAQ:CPIX) issued its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07), Zacks reports. Cumberland Pharmaceuticals had a negative net margin of 17.60% and a negative return on equity of 12.01%.

Here are the key takeaways from Cumberland Pharmaceuticals’ conference call:

• Apotex transaction closed July 1, delivering $100 million in cash at closing, with an additional $11 million expected from inventory and transition payments and a potential $10 million milestone payment.
• Cumberland declared a $1.50-per-share special dividend totaling approximately $22 million while retaining enough capital to fund operations for more than five years and maintain over $50 million in reserves.
• The company is pivoting fully toward its ifetroban pipeline, with anticipated 2026 milestones including systemic sclerosis top-line results, interim efficacy data from the idiopathic pulmonary fibrosis study, and further regulatory guidance for Duchenne muscular dystrophy.
• Management cited encouraging clinical progress: ifetroban’s DMD study produced supportive biomarker findings, the systemic sclerosis trial completed enrollment, and a Vanderbilt oncology study reported fewer metastatic recurrences and metastasis-related deaths in the treatment arm.
• Following the divestiture, Cumberland will no longer receive revenue from its commercial brands and will operate primarily as a development-stage biopharmaceutical company; second-quarter operating loss was $3.1 million and net loss was $4.1 million.

Cumberland Pharmaceuticals Stock Performance

CPIX traded up $0.62 during midday trading on Tuesday, hitting $7.80. 200,741 shares of the company traded hands, compared to its average volume of 503,979. The company has a quick ratio of 0.79, a current ratio of 0.95 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $116.84 million, a PE ratio of -15.91 and a beta of 0.09. The company’s 50-day moving average is $6.32 and its 200 day moving average is $4.74. Cumberland Pharmaceuticals has a 52 week low of $1.85 and a 52 week high of $8.09.

Cumberland Pharmaceuticals Dividend Announcement

The firm also recently declared a dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, July 23rd were issued a dividend of $1.50 per share.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Wednesday, June 24th. Wall Street Zen cut Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in Cumberland Pharmaceuticals in the 2nd quarter worth approximately $34,000. Two Sigma Investments LP boosted its stake in shares of Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after buying an additional 5,326 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Cumberland Pharmaceuticals in the fourth quarter worth $192,000. Geode Capital Management LLC increased its position in Cumberland Pharmaceuticals by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after acquiring an additional 5,653 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its holdings in Cumberland Pharmaceuticals by 2.3% in the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after acquiring an additional 4,200 shares during the period. 15.51% of the stock is owned by hedge funds and other institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.